HER2 positive breast cancer
Not recruitingStudy on Trastuzumab Deruxtecan, Trastuzumab, and Pertuzumab for Patients with HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer
Study on Trastuzumab Deruxtecan, Trastuzumab, and Pertuzumab for Patients with HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer
- Disease:HER2 positive breast cancer
- Substances:PertuzumabTrastuzumab+1
Germany- Participants:18–64 years · 65+ years
- Substances:Pertuzumab
- Sponsor:Medica Scientia Innovation Research S.L.











